Daewon Pharmaceutical Co., Ltd. (KRX:003220)
South Korea · Delayed Price · Currency is KRW 9,780.00
-760.00 (-7.21%)
Jun 10, 2026, 3:30 PM KST
Daewon Pharmaceutical Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Daewon Pharmaceutical stock has a consensus rating of "Strong Buy" and an average price target of ₩14,667. The average 1-year stock price forecast is 49.97% higher than the current stock price, while the lowest is ₩13,000 (+32.92%) and the highest is ₩16,000 (+63.60%).
Price Target: ₩14,667 (+49.97%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Daewon Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | May '25 | Nov '25 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 2 | 2 | 2 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 1 | 1 | 3 | 3 | 3 |
Financial Forecast
Revenue This Year
638.43B
from 605.43B
Increased by 5.45%
Revenue Next Year
680.07B
from 638.43B
Increased by 6.52%
EPS This Year
710.00
from -65.00
EPS Next Year
1.39K
from 710.00
Increased by 95.63%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 662.0B | ||
| Avg | 638.4B | ||
| Low | 568.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 9.3% | ||
| Avg | 5.5% | ||
| Low | -6.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | 710.00 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |